Cargando…
Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?
PURPOSE: Despite evidence supporting at least five years of endocrine therapy for early breast cancer, many women discontinue therapy early. We investigated the impact of initial therapy type and specific comorbidities on discontinuation of endocrine therapy in clinical practice. METHODS: We identif...
Autores principales: | Kemp, Anna, Preen, David B, Saunders, Christobel, Boyle, Frances, Bulsara, Max, Malacova, Eva, Roughead, Elizabeth E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4058005/ https://www.ncbi.nlm.nih.gov/pubmed/24936397 http://dx.doi.org/10.1186/2193-1801-3-282 |
Ejemplares similares
-
Women Commencing Anastrozole, Letrozole or Tamoxifen for Early Breast Cancer: The Impact of Comorbidity and Demographics on Initial Choice
por: Kemp, Anna, et al.
Publicado: (2014) -
Determining breast cancer recurrence following completion of active treatment: A novel approach using linked administrative health data
por: Preen, David, et al.
Publicado: (2017) -
Ascertaining invasive breast cancer cases; the validity of administrative and self-reported data sources in Australia
por: Kemp, Anna, et al.
Publicado: (2013) -
Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk?
por: Corica, Tammy, et al.
Publicado: (2014) -
Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia
por: Seaman, Karla L, et al.
Publicado: (2017)